KROS

Keros Therapeutics, Inc.

63.62 USD
+0.01 (+0.02%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Keros Therapeutics, Inc. stock is up 11.11% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 10 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Jan 19:50 15 Mar, 2024 40.00 CALL 25 259
23 Jan 16:01 15 Mar, 2024 40.00 CALL 25 234
24 Jan 18:00 15 Mar, 2024 40.00 CALL 25 209
24 Jan 20:11 15 Mar, 2024 60.00 CALL 75 199
29 Jan 16:02 15 Mar, 2024 40.00 CALL 25 184
29 Jan 20:55 15 Mar, 2024 40.00 CALL 25 184
06 Feb 14:33 15 Mar, 2024 40.00 CALL 25 137
06 Feb 20:30 15 Mar, 2024 40.00 CALL 25 137
06 Feb 20:33 15 Mar, 2024 40.00 CALL 22 137
16 Feb 20:30 19 Apr, 2024 65.00 CALL 108 0

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia.